关键词： VDR gene polymorphisms   Vitamin D   Inflammatory bowel disease   Crohn's disease   Ulcerative colitis  

摘要： Ulcerative colitis (UC) and Crohn's disease (CD) are the two main forms of inflammatory bowel disease (IBD). IBD is thought to result from an inappropriate and continuing inflammatory response to commensal microbes in a genetically susceptible host. One of hundreds independent SNPs connected to IBD pathogenesis are considered polymorphisms in the gene for vitamin D receptor (VDR). The purpose of the study was to investigate the association of VDR gene polymorphisms FokI, BsmI, ApaI, TaqI with disease susceptibility in 86 Slovak UC and 122 CD patients and in 155 controls. The distribution of VDR (FokI, BsmI, ApaI and TaqI) alleles and genotype variants in Slovak healthy population is analogous to those of other Caucasoid populations. The distributions of FokI genotypes in CD patients showed significant Hardy-Weinberg equilibrium (HWE) deviation (P = 0.0062) with considerable shortage of heterozygosity compared to controls (36.89 vs. 47.67%;OR = 0.5479;95%CI = 0.3376-0.8892). We did not find any significant association of FokI, BsmI, ApaI and TaqI variants with localisation of UC or CD manifestation as well as the age of onset in case of Crohn's disease. Our study showed for the first time in Slovak population that the FokI polymorphism can be involved in susceptibility to Crohn's disease development. However, we did not find any association of FokI, BsmI, ApaI and TaqI SNPs with clinical features of CD and UC.

关键词： HIV Infections   Inflammatory Bowel Diseases   Spirochaetales Infections   Intestinal Diseases   Patients  

关键词： Claims data   Herpes zoster   Inflammatory bowel disease  

摘要： Background/Aims: The risk of herpes zoster (HZ) among patients with inflammatory bowel disease (IBD) remains unclear in terms of age and metabolic comorbidities, including diabetes mellitus, hypertension, or dyslipidemia. We conducted a nationwide population-based study to investigate the risk of HZ in patients with IBD. Methods: From 2010 to 2013, a retrospective study was performed using claims data in Korea. We compared the incidence of HZ between 30,100 IBD patients (10,517 Crohn's disease [CD] and 19,583 ulcerative colitis [UC] patients) and 150,500 non-IBD controls matched by age and sex. Results: During a mean follow-up of 5.0 years, incidence rates of HZ (per 1,000 person-years) were 13.60, 14.99, and 9.19 in the CD, UC, and control groups, respectively. The risk of HZ was significantly higher in patients with CD (adjusted hazard ratio [HR], 2.13;p<0.001) and UC (adjusted HR, 1.40;p<0.001) than in the controls. The impact of CD on developing HZ was significantly more prominent in younger patients (adjusted HR, 2.61 for age <15, whereas 1.39 for age >= 60;interaction p=0.001) and in patients without metabolic comorbidities (adjusted HR, 2.24, whereas 1.59 in those with metabolic comorbidities;interaction p=0.015). Moreover, the impact of UC on developing HZ significantly increased in younger patients (adjusted HR, 2.51 in age <15, whereas 1.22 in age >= 60;interaction p=0.014) and patients without metabolic comorbidities (adjusted HR, 1.49 whereas 1.16 in those with metabolic comorbidities;interaction p<0.001). Conclusions: IBD was associated with an increased risk of HZ, especially in younger patients without metabolic comorbidities.

关键词： Inflammation   Hyaluronan   Inflammatory bowel disease   Platelet   Megakaryocyte   Coagulation  

摘要： Hyaluronan, a major extracellular matrix component, is an active participant in many disease states, including inflammatory bowel disease (IBD). The synthesis of this dynamic polymer is increased at sites of inflammation. Hyaluronan together with the enzymes responsible for its synthesis, degradation, and its binding proteins, directly modulates the promotion and resolution of disease by controlling recruitment of immune cells, by release of inflammatory cytokines, and by balancing hemostasis. This review discusses the functional significance of hyaluronan in the cells and tissues involved in inflammatory bowel disease pathobiology. (C) 2018 Elsevier B.V. All rights reserved.

关键词： Crohn's Disease   Inflammatory Bowel Disease   Roma/Gypsy ethnicit   Ulcerative Colitis  

摘要： Background: Peculiarities of inflammatory bowel disease (IBD) have been explored in ethnic groups, such as Asians, Hispanics, and Afro-Americans, but not in other ethnic minorities, such as Roma/Gypsies. Methods: In a retrospective, hospital-based study, all adult Roma/Gypsy patients included in the IBD databases of seven Spanish centres were identified as cases. For each Roma/Gypsy patient, a Caucasian patient, matched for several demographic features, was searched as a control. Data on phenotypic features, therapeutic requirements, and familial aggregation were recorded. Results: Sixty-eight Roma/Gypsy patients were identified, 29 of them being women. The mean age at diagnosis of IBD was 24.9 +/- 9.5 years, and the mean time elapsed since diagnosis was 96.6 +/- 72.2 months. Roma/Gypsy IBD patients showed a significantly higher rate of familial aggregation (43%) than their Caucasian controls (9%) (p = 0.00001). CD in Roma/Gypsies had more often a complicated pattern (mainly penetrating) while UC patients showed a marked trend to more often developing extraintestinal manifestations. In addition, Roma/Gypsy IBD patients had a somewhat greater need for immunosuppressants, biological agents or surgery. Conclusions: These are the first data on IBD in Roma/Gypsy patients. Familial aggregation is the most prominent feature in these patients, suggesting a predominant role of genetics in its pathogenesis. (C) 2018 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.

关键词： Anti-TNF alpha   Biosimilars   Crohn's disease   Inflammatory bowel disease   Tumor necrosis factor alpha   Ulcerative colitis  

摘要： The first infliximab biosimilar for the treatment of inflammatory bowel disease (IBD) was introduced in 2013, and today eight anti-TNF alpha biosimilars (three for infliximab and five for adalimumab) have been approved and licensed by the European Medicines Agency. Biosimilars present great potential in terms of cost saving and possible consequential reinvestment in the health care system. The increasing knowledge about the process of biosimilar development and use in IBD and the publication of many prospective clinical studies and real-life clinical experiences have progressively changed the point of view of IBD physicians. In the present position paper, the Italian Group for the Study of Inflammatory Bowel Disease present and discuss their updated statements and positions on this topic, with emphasis on the concepts of biosimilarity and extrapolation across indications, safety and immunogenicity, interchangeability and switching, automatic substitution, and, finally, patient education about biosimilars. (C) 2019 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.